Pharmaceutical aluminium foil for tablet, capsule, granule, and injection packaging is supplied in alloys AA 8011, AA 8021, and AA 8079, with thicknesses of 20 µm, 25 µm, 30 µm, 45 µm, and 60 µm. A representative designation PAF-25/8011-O/HSL encodes a 25 µm annealed foil in AA 8011 with a heat-seal lacquer; equivalent designations cover cold-form base foil, peelable lidding, and printed cap stock. The material is supplied as slit coils with core ID 76 mm or 152 mm, web widths from 300 mm to 1000 mm, and splice-free lengths matched to blister-line reel dimensions. Dimensional tolerances are controlled to EN 546-3, tensile properties are tested according to ASTM E345/E345M, and pinholing is evaluated by light-table inspection under EN 546-4 or an agreed equivalent. Release documentation follows ISO 15378:2017 as the primary packaging quality system, with certificate of compliance, certificate of analysis, and GMP declaration supplied for each lot.

Manufacturing begins with double-zero foil stock cold-rolled to final gauge, followed by annealing in batch furnaces with controlled atmosphere to achieve specified softness, surface cleanliness, and levelling. Coating and printing are performed on gravure or flexographic lines with in-line corona or plasma treatment. Slitting is performed on high-speed rewind slitters where web tension, edge quality, and splice count are monitored because edge cracks and stretch marks can become pinhole sources in finished blisters. Each slit reel carries a unique barcode linked to the original coil and coating batch; this traceability supports complaint investigation and recall under pharmaceutical GMP.

Pharma-grade foil is a primary contact packaging material, not an active pharmaceutical ingredient. For injectable formats it is usually supplied as a lacquered cap membrane or sealing component, with only the coated or laminated side exposed to the closure environment. The foil requires storage at ≤ 60% RH and should not be exposed to temperatures above 40 °C for extended periods before conversion. If moisture-sensitive adhesives or primers are used, reconditioning or controlled drying is necessary.

What Distinguishes Pharmaceutical-Grade Foil from Converter-Grade Aluminum?

The main difference is not base alloy chemistry. Converter-grade and pharma-grade material may both be 20 µm AA 8011-O foil, but the pharmaceutical grade is released against a Quality Agreement specifying pinhole acceptance limits, residual oil after annealing, surface wetting tension, splice frequency, and seal-strength verification on the customer's blister base material. Converter-grade foil may be ordered against EN 546 alone and released on dimensional and visual inspection without pharmaceutical attribute testing. In pharmaceutical lot disposition, foil is tested for residual solvents by headspace gas chromatography, pinhole count on a backlit light bench, and heat-seal strength after coating or lamination; each test is linked to a unique slit reel and traceable to the original annealing coil.

Compared with household-grade foil, pharma-grade foil has a lower pinhole population, tighter thickness tolerance, controlled residual oils, and a documented quality system. Compared with food-container lidding, the pharmaceutical product is typically produced from virgin smelter aluminium or tightly segregated internal scrap rather than post-consumer scrap, and avoids migration-positive additives. These differences are stated in the supplier declaration of compliance and can be audited through lot-level raw-material traceability.

Cold-form alu-alu laminates use 45 µm to 60 µm foil, usually AA 8021-O or AA 8079-O, laminated on the outside to 25 µm oriented polyamide and on the inside to 60 µm PVC or a polyolefin sealing layer. In production-scale cold forming with plug-assisted tooling, the foil must elongate in multiple directions without necking or tearing. Incoming tensile elongation measured by ASTM E345/E345M is commonly specified above 12% for 45 µm foil, and limiting dome height on a cup fixture is used as a release criterion. Selection of AA 8021 over AA 8011 is made when cavity depth exceeds the formability limit of AA 8011; AA 8021 is processed to a finer grain structure and shows lower earing in multi-cavity cold-form blisters. Published data for limiting dome height under specific cavity geometries is limited; suppliers rely on cupping test, tensile elongation, and pinhole data for batch release.

Cold-Form Foil Drawability and Moisture Barrier Thresholds

The moisture barrier of a 45 µm cold-form laminate is usually specified as water vapour transmission rate below 0.005 g/m²·24 h at 38 °C and 90% RH. This value is a widely referenced threshold for high-barrier alu-alu packaging, but it is a laminate property rather than a foil property because pinholes, flex cracks, and seal failures dominate moisture ingress. A cold-form blister with 45 µm foil can still lose barrier if cavity corners are over-thinned during forming; minimum wall thickness after forming is therefore monitored on microsectioned cavities and specified by the laminate supplier. On a high-speed cold-form line, a 45 µm foil laminate is generally formed to cavity depths of 6–10 mm depending on cavity diameter, plug geometry, and tooling radius. Corner thinning is measured on cross-sectioned cavities and the minimum remaining aluminium layer is used to predict pinhole risk after flexing.

On the lidding side, foil is printed by rotogravure or flexographic processes, then primed and coated with heat-seal lacquer on the inner side. Surface wetting tension after pre-treatment is typically maintained at 38–42 dyn/cm for adhesion of solvent-based or solvent-free primers. Heat-seal lacquer selection is matched to the cavity polymer: vinyl/PVDC-compatible lacquers generally seal at 150–180 °C jaw temperature, while PP- or COC-based cavities may require 170–200 °C. Sealing pressure and dwell time on the specific blister machine are decisive; an internal seal-strength lower limit of 4–8 N/15 mm is often used for non-peelable lidding, but published specifications vary by package design and test geometry.

When a 25 µm Foil Is Replaced by a 20 µm Foil in Blister Lidding

Reducing lidding foil from 25 µm to 20 µm lowers coil weight and material cost but changes pinhole probability and push-through opening force. Pinhole formation is thickness-dependent during final rolling, so a 20 µm foil must demonstrate equivalent pinholing under EN 546-4 at the same light intensity as the thicker control. Tensile tear resistance also decreases with gauge, and child-resistant non-reclosable packaging may require retesting under EN 14375 or ISO 8317 to confirm that opening by a test panel remains within the specified tear path. For moisture-sensitive tablets, capsules, or granules, a full stability protocol under ICH Q1A is required before down-gauging is accepted on a commercial blister line.

Injectable and oral liquid applications use lacquered aluminium foil as a cap membrane or seal in flip-off and tear-off closures, supplied in 20–25 µm thickness. The material is usually printed in gravure up to seven colours, coated with a heat-seal finish, and punched on high-speed capping equipment at 200–600 caps/min. Residual lubricants after slitting and lacquer curing must be controlled to prevent particle generation in the sterile area; foil for injectable seals is therefore handled in dedicated clean areas and subjected to particulate testing on finished caps. Sterilisation compatibility depends on the coating system: autoclaving at 121 °C, gamma irradiation, or ethylene oxide exposure requires extractables data for the coated foil under the selected cycle. Published data for a specific injectable seal configuration is limited because pharmaceutical qualification is performed on the finished closure system, not on the foil in isolation.

Particulate release and extractables must be controlled at the punch-lacquer interface

Injectable cap foils place additional limits on aluminium dust, lacquer particles, and extractable residues after punching and capping. The lacquer system must show no visible delamination after die cutting at high speed; coin test and tap test are used in production to detect lacquer adhesion failure. Residual solvents in printed lacquer are measured by headspace gas chromatography and controlled to limits agreed in the packaging specification. For pharmaceutical-grade foil intended for oral solid dose forms, a lower level of particulate control is typically accepted, but the same incoming pinholing and seal-integrity release criteria remain applicable. If the foil is used in contact with PVDC or PVC, hydrochloric acid or plasticiser migration can alter seal strength after 6 months at 40 °C / 75% RH; this is evaluated by packaging stability rather than by foil certificate alone.

Difference from PVDC-coated PVC film is substantial: a 250 µm PVDC-coated PVC cavity typically has a WVTR in the range 0.1–0.3 g/m²·24 h at 38 °C / 90% RH, while a 45 µm alu-alu laminate is specified below 0.005 g/m²·24 h. Transparent PET or paper-based lidding can be used where transparency or lower cost is required, but neither provides the aluminium foil’s barrier and push-through control. The aluminium product is therefore selected when the dosage form is hygroscopic, oxygen-sensitive, or requires high child-resistance or moisture protection for tropical markets.

For granules and powders with abrasive fillers, foil lidding may require an additional primer or a thickness increase to 25–30 µm to prevent flex-crack pinholes during high-speed filling and sealing. Use of solvent-based inks and lacquers requires controlled drying to residual solvent limits before slitting, because retained solvent can create blocking and seal failure. The foil must be stored in original moisture-resistant packaging at ≤ 60% RH and converted within the supplier-specified shelf life after surface treatment.